Novavax Selects AGC Biologics to Manufacture Matrix-M Adjuvant for Novel COVID-19 Vaccine
AGC Biologics, a global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced that it will partner with Novavax, Inc. a late-stage biotechnology…
Read More...
Read More...
